Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 86.68 as of 2026-10-06T18:09:24.991Z.
Consensus retrieved: 2026-10-06T15:50:41.336Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:09:24.991Z.
Quote observation: 2026-10-06T18:05:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2355af3827b8d6f3d1f03de76b7a2de51d815fa7b300e2f75a1d67e8915773
Forward PE Ratio (86.68) = Dated Quote Price ($178.50) / Consensus Forward EPS ($2.06)
FORWARD PE RATIO
86.68
SECTOR MEDIAN · HEALTHCARE
19.85
median of 189 covered companies
CURRENT VS SECTOR MEDIAN
+336.68%
vs the sector median at left
Repligen Corporation
Market Cap
$10.07B
Forward PE Ratio
86.68
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Repligen Corporation (RGEN) | $10.07B | 86.68 |
| Molina Healthcare, Inc. (MOH)vs › | $10.05B | N/A |
| The Ensign Group, Inc. (ENSG)vs › | $10.09B | 22.20 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $10.01B | 38.14 |
| Align Technology, Inc. (ALGN)vs › | $10.21B | 12.62 |
| ImmunityBio, Inc. (IBRX)vs › | $10.28B | N/A |
| Globus Medical, Inc. (GMED)vs › | $10.38B | 15.40 |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 15.77 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.59B | 42.75 |
| 10x Genomics, Inc. (TXG)vs › | $10.57B | N/A |
Trailing P/E
244.5
reported TTM EPS
Forward P/E
86.7
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.06 implies +182.2% EPS growth vs the reported trailing $0.73.
At the dated quote price of $178.50, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.06 | $2.05 – $2.08 | 11 | 86.7x |
| 2027-12-31 | $2.63 | $2.49 – $2.74 | 11 | 67.8x |
| 2028-12-31 | $3.46 | $3.19 – $4.07 | 6 | 51.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
